antibody technology

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available,...

Total money raised: $62M


3015 Dr Molewaterplein 50


Phone: +31 (0)10 70 38 441

Updated on Nov 4, 2013
arGEN-X at CrunchBase

December, 2011

arGEN-X raised $43.9M in a Series B round from OrbiMed Advisors, Forbion Capital Partners, Crédit Agricole Private Equity, LSP BioVentures, Erasmus MC Biomedical Fund, Seventure Partners, and PMV-Vinnof

arGEN-X Closes €27.5M Series B Funding Round

February, 2010

arGEN-X raised $4.5M in a Series A round from Crédit Agricole Private Equity, Forbion Capital Partners, Life Sciences Partners, KBC, BioGeneration Ventures, Erasmus MC Biomedical Fund, and Thuja Capital

arGEN-X, BV: Series A $4.5M

September, 2009

arGEN-X raised $13.6M in a Series A round from Forbion Capital Partners, KBC, BioGeneration Ventures, and Erasmus MC Biomedical Fund

arGEN-X gins $13.6M in new funds for mAB work